Clinical and laboratory findings | Anti-ARS | Anti-CADM-140/MDA5 | Anti-Mi-2 | Anti-p155/TIF1-γ | Negative |
(n = 27) | (n = 19) | (n = 5) | (n = 8) | (n = 36) | |
Age at onset (mean ± SD) | 52 ± 14 | 53 ± 13 | 55 ± 17 | 62 ± 20 | 51 ± 14 |
Male/female | 8/19 | 5/14 | 2/3 | 2/6 | 7/29 |
Gottron’s sign or papules (%) | 67 | 84 | 80 | 88 | 78 |
Heliotrope rash (%) | 37 | 37 | 80 | 38 | 56 |
V-sign or Shawl-sign (%) | 15 | 37 | 40 | 63 | 31 |
Muscle weakness (%) | 93 | 11 | 100 | 88 | 81 |
Elevation of CK (%) | 93 | 26 | 100 | 88 | 78 |
Fever (%) | 63 | 68 | 20 | 25 | 53 |
Arthritis (%) | 81 | 79 | 60 | 13 | 50 |
Raynaud’s phenomenon (%) | 30 | 5 | 0 | 13 | 6 |
ILD (%) | 81 | 89 | 0 | 13 | 50 |
Rapidly progressive ILD (%) | 7 | 84 | 0 | 0 | 8 |
Malignancy (%) | 7 | 5 | 0 | 75 | 19 |
ANA (FANA) (%) | 44 | 16 | 100 | 88 | 36 |